Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
2
33%
Ph phase_3
1
17%
Ph phase_4
3
50%

Phase Distribution

2

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
3(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (33.3%)
Phase 31 (16.7%)
Phase 43 (50.0%)

Trials by Status

terminated233%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_4

C-Cog in Early Course Schizophrenia Study

NCT05662306
terminatedphase_4

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

NCT04203056
completedphase_3

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

NCT03345979
completedphase_4

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

NCT02634320
completedphase_1

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

NCT02320032
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05662306Phase 4

C-Cog in Early Course Schizophrenia Study

Terminated
NCT04203056Phase 4

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

Terminated
NCT03345979Phase 3

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

Completed
NCT02634320Phase 4

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

Completed
NCT02320032Phase 1

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Completed
NCT02636842Phase 1

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6